39,43 €
0,01 % heute
L&S, 31. Oktober, 08:13 Uhr
ISIN
US1101221083
Symbol
BMY
Berichte

Bristol-Myers Squibb Aktie News

Neutral
Seeking Alpha
etwa 11 Stunden alt
Bristol-Myers Squibb Company ( BMY ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Chuck Triano Christopher Boerner - CEO & Chairman David Elkins - Executive VP & CFO Cristian Massacesi - Executive VP, Chief Medical Officer & Head of Development Adam Lenkowsky - Executive VP & Chief Commercialization Officer Conference Call Participants Christopher Schott - JPMorgan Ch...
Negativ
Seeking Alpha
etwa 14 Stunden alt
Bristol-Myers Squibb Company's Q3 earnings are out - beating analyst's estimates - and for once, stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose patent protection, leading to revenue declines despite a strong dividend yield. Recent acquisitions and new product launches have underperformed versus management's ambitious targets, raising concerns ab...
Positiv
Seeking Alpha
etwa 15 Stunden alt
The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-priced GASV stocks, including ET, MPLX, YRD, VZ, BMY, TFC, T, SU, MFC, and BBVA, are considered buyable in October. Analyst projections suggest the top ten GASV stocks could deliver average net gai...
Positiv
24/7 Wall Street
etwa 18 Stunden alt
While many seniors have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.
Neutral
Barrons
etwa 20 Stunden alt
While total revenue grew in the quarter, competition weighed on the drugmaker's legacy portfolio.
Positiv
WSJ
etwa 20 Stunden alt
Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.
Positiv
Reuters
etwa 20 Stunden alt
Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from generic competition for several older drugs.
Neutral
Business Wire
etwa 20 Stunden alt
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen